drugset / Trial / NCT05278611
a Safety and Tolerability Study of EP-9001A in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindBasic science
Summary
Nerve Growth Factor（NGF）plays an important role in the pathogenesis of neuropathic pain including cancer pain. EP-9001A is a humanized monoclonal antibody targeting NGF, thus thought to alleviate neuropathic pain though the blockade of NGF signal pathway. The primary objective of the study is to assess the safety and tolerability of a single dose of subcutaneous (SC) administered EP-9001A in healthy Chinese subjects.
Timeline
- Start
- 2022-03-23
- Primary completion
- 2022-09
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EP-9001A | Unknown | 1 mg | Subcutaneous |
| Subject | EP-9001A | Unknown | 2.5 mg | Subcutaneous |
| Subject | EP-9001A | Unknown | 5 mg | Subcutaneous |
| Subject | EP-9001A | Unknown | 10 mg | Subcutaneous |
| Subject | EP-9001A | Unknown | 20 mg | Subcutaneous |
| Subject | EP-9001A | Unknown | 25 mg | Subcutaneous |
Indications
No indication recorded.